There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come.
The market kicks off with TrustCo (NASDAQ: TRST ) reporting quarterly results on Monday. Many of the "too big to fail" institutions reported in recent days, but now it's time to check out some of the regional players. TrustCo has 138 offices through the Northeast and Florida, watching over $4.3 billion in assets.
AK Steel (NYSE: AKS ) hopes to "steel" the show on Tuesday. The producer of flat-rolled carbon, stainless, and electrical steels is expected to post another quarterly deficit. AK Steel provided guidance last month that calls for a sequential dip in production. It was expecting to ship between 1.275 million and 1.3 million tons of steel during the first three months of the year, and that's less than the more than 1.4 million tons it shipped during the fourth quarter of last year.
The good news is that analysts are expecting a substantially narrower loss out of AK Steel than it rolled out during the prior year's freshman quarter.
New York Community Bancorp (NYSE: NYCB ) is another regional banker reporting this week. One of its more notable features is its chunky dividend. A hefty yield of 7.3% will turn heads in just about any industry, but is it sustainable? Analysts see slight dips in revenue and earnings per share in Wednesday's report.
Tellabs (NASDAQ: TLAB ) checks in on Thursday. The provider of mobile backhaul, packet optical, and services solutions to communications services lost its CEO to colon cancer last year. It has also lost its mojo. Wall Street sees Tellabs merely breaking even in 2013 on a 14% decline in revenue.
The market is typically quiet on Friday, but that's certainly not the case during earnings season. AbbVie's (NYSE: ABBV ) report will be the branded medicine marketer's first public quarter as a standalone company since being spun off by Abbot Labs in January. Abbot Labs itself posted encouraging results a few days ago. Now it's time to see how AbbVie holds up.
Abbott Labs has changed forever after losing its branded pharmaceutical business to a spinoff. If you're a current investor, or might be buying shares soon, make sure you truly understand the stock by reading The Motley Fool's brand new premium report on Abbott Labs. The report outlines all of the must-know opportunities and risks, along with a full year of analyst updates to keep you up to speed. Best of all, you can claim this report today by clicking here now.